No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 6 | 9 | 11 | 12 | 12 | 12 | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | -3 | -0 | 0 | -1 | -2 | -1 | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and precision engineering applications. Its global presence extends across the UK, Europe, the Asia Pacific region, and the United States. The company operates through three distinct divisions: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The SI Brand segment is responsible for the research, development, production, and commercialization of its proprietary SI-branded minimally invasive instruments. Key products within this portfolio include the YelloPort Elite and YelloPort +plus laparoscopic port access systems, LogiRange resposable laparoscopic instrument systems, FastClamp laparoscopic clamping systems, and QuickRange single-use laparoscopic instrumentation. The OEM division focuses on crafting and supplying minimally invasive devices for third-party medical device firms, often under their own brand or through co-branding arrangements. This segment also provides comprehensive design and development solutions for creating final medical devices and is involved in the research, development, manufacturing, and sale of minimally invasive technology tailored for precision engineering. Lastly, the Distribution segment handles the supply of various medical products, primarily via its subsidiary, Elemental Healthcare Ltd, and also designs and produces autologous blood products. Surgical Innovations Group plc sells its offerings through a network of independent healthcare distributors, while its own-label products are also distributed through its OEM collaborations.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Surgical Innovations Group plc (SUN.L)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and precision engineering applications. Its global presence extends across the UK, Europe, the Asia Pacific region, and the United States. The company operates through three distinct divisions: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The SI Brand segment is responsible for the research, development, production, and commercialization of its proprietary SI-branded minimally invasive instruments. Key products within this portfolio include the YelloPort Elite and YelloPort +plus laparoscopic port access systems, LogiRange resposable laparoscopic instrument systems, FastClamp laparoscopic clamping systems, and QuickRange single-use laparoscopic instrumentation. The OEM division focuses on crafting and supplying minimally invasive devices for third-party medical device firms, often under their own brand or through co-branding arrangements. This segment also provides comprehensive design and development solutions for creating final medical devices and is involved in the research, development, manufacturing, and sale of minimally invasive technology tailored for precision engineering. Lastly, the Distribution segment handles the supply of various medical products, primarily via its subsidiary, Elemental Healthcare Ltd, and also designs and produces autologous blood products. Surgical Innovations Group plc sells its offerings through a network of independent healthcare distributors, while its own-label products are also distributed through its OEM collaborations.
